Literature DB >> 17304245

Strategies for silencing human disease using RNA interference.

Daniel H Kim1, John J Rossi.   

Abstract

Since the first description of RNA interference (RNAi) in animals less than a decade ago, there has been rapid progress towards its use as a therapeutic modality against human diseases. Advances in our understanding of the mechanisms of RNAi and studies of RNAi in vivo indicate that RNAi-based therapies might soon provide a powerful new arsenal against pathogens and diseases for which treatment options are currently limited. Recent findings have highlighted both promise and challenges in using RNAi for therapeutic applications. Design and delivery strategies for RNAi effector molecules must be carefully considered to address safety concerns and to ensure effective, successful treatment of human diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17304245     DOI: 10.1038/nrg2006

Source DB:  PubMed          Journal:  Nat Rev Genet        ISSN: 1471-0056            Impact factor:   53.242


  329 in total

1.  A rapid pathway toward a superb gene delivery system: programming structural and functional diversity into a supramolecular nanoparticle library.

Authors:  Hao Wang; Kan Liu; Kuan-Ju Chen; Yujie Lu; Shutao Wang; Wei-Yu Lin; Feng Guo; Ken-ichiro Kamei; Yi-Chun Chen; Minori Ohashi; Mingwei Wang; Mitch André Garcia; Xing-Zhong Zhao; Clifton K-F Shen; Hsian-Rong Tseng
Journal:  ACS Nano       Date:  2010-10-26       Impact factor: 15.881

2.  Use of siRNA in knocking down of dopamine receptors, a possible therapeutic option in neuropsychiatric disorders.

Authors:  Mohammad-Reza Noori-Daloii; Majid Mojarrad; Ali Rashidi-Nezhad; Majid Kheirollahi; Ali Shahbazi; Mehdi Khaksari; Asghar Korzebor; Ali Goodarzi; Maryam Ebrahimi; Ali Reza Noori-Daloii
Journal:  Mol Biol Rep       Date:  2011-06-03       Impact factor: 2.316

Review 3.  RNA interference trigger variants: getting the most out of RNA for RNA interference-based therapeutics.

Authors:  Nicholas M Snead; John J Rossi
Journal:  Nucleic Acid Ther       Date:  2012-06       Impact factor: 5.486

Review 4.  Molecular diagnostics in transplantation.

Authors:  Maarten Naesens; Minnie M Sarwal
Journal:  Nat Rev Nephrol       Date:  2010-08-24       Impact factor: 28.314

Review 5.  microRNAs in heart disease: putative novel therapeutic targets?

Authors:  Gianluigi Condorelli; Michael V G Latronico; Gerald W Dorn
Journal:  Eur Heart J       Date:  2010-01-29       Impact factor: 29.983

6.  Titers of lentiviral vectors encoding shRNAs and miRNAs are reduced by different mechanisms that require distinct repair strategies.

Authors:  Ying Poi Liu; Monique A Vink; Jan-Tinus Westerink; Eva Ramirez de Arellano; Pavlina Konstantinova; Olivier Ter Brake; Ben Berkhout
Journal:  RNA       Date:  2010-05-24       Impact factor: 4.942

7.  Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice.

Authors:  Jiehua Zhou; C Preston Neff; Xiaoxuan Liu; Jane Zhang; Haitang Li; David D Smith; Piotr Swiderski; Tawfik Aboellail; Yuanyu Huang; Quan Du; Zicai Liang; Ling Peng; Ramesh Akkina; John J Rossi
Journal:  Mol Ther       Date:  2011-09-27       Impact factor: 11.454

Review 8.  Current progress in the development of RNAi-based therapeutics for HIV-1.

Authors:  J Zhou; J J Rossi
Journal:  Gene Ther       Date:  2011-09-29       Impact factor: 5.250

9.  Lentivirus vector-mediated knockdown of erythropoietin-producing hepatocellular carcinoma receptors B4 inhibits laser-induced choroidal neovascularization.

Authors:  Jing Du; Wei Zhao; Yusheng Wang; Yan Cai
Journal:  J Ocul Pharmacol Ther       Date:  2012-10-04       Impact factor: 2.671

10.  Hypoxia-targeted siRNA delivery.

Authors:  F Perche; S Biswas; T Wang; L Zhu; V P Torchilin
Journal:  Angew Chem Int Ed Engl       Date:  2014-02-19       Impact factor: 15.336

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.